ANDA 91041, held by Sagent Pharms Inc. Octreotide Acetate.
As of Nov 16, 2026, ANDA 91041 (Octreotide Acetate), held by Sagent Pharms Inc, was first approved by FDA on Nov 12, 2013, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 12, 2013 | Original application | Approved | None posted |
| Octreotide AcetateEQ 0.2MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Aug 27, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 10, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 12, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters